Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease:A review of preliminary data,efficacy,and cost

作     者：Alan D.Workman Benjamin S.Bleier Workman Alan D.;Bleier Benjamin S.

作者机构：Department of OtolarynsologyMassachusetts Eye and Ear InfirmaryHarvard Medical SchoolBostonM Af USA 

出 版 物：《World Journal of Otorhinolaryngology-Head and Neck Surgery》 (世界耳鼻咽喉头颈外科杂志（英文）)

年 卷 期：2020年第6卷第4期

页      面：230-234页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 100213[医学-耳鼻咽喉科学] 10[医学] 

主　　题：CRSwNP AERD Biologics Omalizumab Dupilumab 

摘      要：Aspirin-exacerbated respiratory disease(AERD)patients with CRSwNP suffer from reduced quality of life,reduced economic productivity,and higher risk of depression and sleep *** patients often require frequent medical and surgical therapy,including functional endoscopic sinus surgery for recalcitrant *** this severity,anti-type 2 biologic treatments are being investigated for use in this subgroup of patients with CRSwNP,including Omalizumab and *** data suggests that SNOT-22 related quality of life improvements following treatment with biologies are comparable to the current standard of care in the short term,but there is a lack of long-term data and standardized regimen that makes direct comparison *** therapies additionally require continuous use to avoid recurrence,and currently cost many times more than existing medical or surgical therapies.